A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)

This study will compare the effectiveness of three different FDA approved drugs for the treatment of skin vasculitis, look at how participants respond to the drugs, and see if there are characteristics that predict, in the future, which patients will respond to which drugs. Participants are randomly assigned to 1 of the 3 drugs.

ClinicalTrials.gov ID: NCT02939573

Study Duration: 12 to 18 months

Disease(s): Cutaneous Polyarteritis Nodosa (cPAN), Immunoglobulin A Vasculitis (IgA), Skin Vasculitis